We added the following clinical trials for HR-positive, HER2-positive, triple-negative, and other subtypes of metastatic (stage IV) breast cancer to Metastatic Trial Search last month.
Stage IV HER2-Positive Trials
- ARX788 for HER2 Positive or HER2 Mutated Advanced Breast Cancer
- Atezolizumab With Tivozanib for Metastatic Hormone Negative, HER2 Positive Breast Cancer
- DB-1303 for Advanced HER2 Expressing Breast Cancer
Stage IV HR-Positive Trials
- Imlunestrant for Advanced ER+, HER2- Breast Cancer
- Capecitabine with Cemiplimab for Hormone Receptor Positive, HER2 Negative Advanced Breast Cancer
- Mirdametinib with Fulvestrant for Advanced ER+ Breast Cancer with a NF1 or MEK1/2 Mutation
Stage IV Triple-Negative Breast Cancer
- Pembrolizumab/Vibostolimab for Advanced Triple Negative Breast Cancer That is PD-L1 Positive
- MDNA11 Immunotherapy for Advanced Triple Negative Breast Cancer
- Uliledlimab With Atezolizumab for Advanced Triple-Negative, PD-L1 Positive Breast Cancer
- Preventing High Blood Sugar in People with Metastatic ER+, HER2- Breast Cancer with a PIK3CA Mutation
- Radiation with Chemotherapy and Immunotherapy for Advanced PD-L1 Positive, Triple Negative Breast Cancer
Other Stage IV Trials
- RLY-2608 Alone and With Fulvestrant for Advanced Breast Cancer with a PIK3CA Mutation
- Stereotactic Radiation with Activation and Guidance of Irradiation by X-ray for Brain Metastases
- P-MUC1C-ALLO1 CAR-T Cell Immunotherapy for Advanced Breast Cancer
- DECT Imaging Before Stereotactic Radiosurgery to Detect Brain Metastases
- Idronoxil with External Beam Radiotherapy for Advanced Breast Cancer
Last Modified on April 6, 2022
